D. Western Therapeutics Institute: Consolidated financial results for the six-month period ended June 30, 2024 (based on Japanese accounting standards).
D. Western Therapeutics Institute: Announcements of monthly exercise status for the 12th subscription rights (with exercise price adjustment clause).
D. Western Therapeutics Institute: Policy regarding the re-application of the nerve pain treatment drug "DW-5LBT".
D. Western Therapeutics Institute: Announcements of individual stocks: Notification of Receipt of Approval Notification for Neurological Pain Treatment Drug, DW-5LBT.
D. Western Therapeutics Institute: Announcement of the mass exercise of the 12th subscription rights (with exercise price adjustment clause).
D. Western Therapeutics Institute: Announcements of monthly exercise status for the 12th subscription rights (with exercise price adjustment clause).
D.WESTERN THERAPEUTICS INST: Consolidated financial results for the three months ended 2024/3/31 (based on Japanese accounting standards)
D. Western Therapeutics Institute: Corporate Governance Report
D.Western Therapeutics Institute: Notice of Submission of Clinical Trial Plan Notification for Regenerative Medicine Cell Product “DWR-2206”
D. Western Therapeutics Institute: [Delayed]Consolidated Financial Results for the Fiscal Year Ended December 31, 2023 (Based on Japanese GAAP)
D. Western Therapeutics Institute: Matters relating to business plans and growth potential
D. Western Therapeutics Institute: Notice of acceptance of the application for approval of the nerve pain medication “DW-5LBT” in the United States
D. Western Therapeutics Institute: Application for approval of the nerve pain medication “DW-5LBT”
D. Western Therapeutics Institute: Independent Officer Registration Form
D. Western Therapeutics Institute: When to apply for approval for the nerve pain medication “DW-5LBT”
D. Western Therapeutics Institute: Notice of resignation of director who is a member of the Audit and Supervisory Committee
D. Western Therapeutics Institute: [Delayed]Summary of Consolidated Financial Results for the Nine Months Ended September 30, 2023(Based on Japanese GAAP)
D. Western Therapeutics Institute: Prospects for reapplying for the nerve pain treatment drug “DW-5LBT”
D. Western Therapeutics Institute: Notice of receipt of the examination completion report notification for the nerve pain treatment drug “DW-5LBT”
D. Western Therapeutics Institute: Notice of commencement of administration of the glaucoma drug “H-1337” to test subjects in the late US phase II clinical trial
No Data